We combine decades of expertise with advanced technologies to lead in the development and manufacturing of the highest quality controlled substance APIs and drug product.
Benuvia stands at the forefront of small molecule controlled substance development, manufacturing, and commercialization. Our expertise spans cannabinoids, psychedelics, and Schedule I–V compounds. Rigorous Quality Control processes ensure every product meets the highest standards of purity, potency, and compliance, safeguarding integrity at every stage. Combined with our deep understanding of DEA, FDA, and global regulatory standards, we provide unparalleled reliability and success in even the most complex markets.
Benuvia combines advanced expertise and cutting-edge facilities to manufacture controlled substance small molecule APIs and drug products with precision and compliance. Our cGMP-certified processes ensure unmatched quality, making us the trusted choice for synthetic cannabinoids and psychedelics.
IUPAC Chemical Name:
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Common Synonyms:
(-)-trans-Cannabidiol, Delta-1(2)-trans-Cannabidiol, Resorcinol 2-p-mentha-1,8-dien-3-yl-5-pentyl-trans-(-)-
CAS Number: 13956-29-1
DEA Schedule: Not Scheduled
Controlled Substances Code Number (CSCN): NA
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from the Cannabis sativa plant. It is widely studied for its potential therapeutic applications, particularly in the treatment of epilepsy, anxiety, chronic pain, and inflammation. CBD interacts with the endocannabinoid system, influencing receptors such as CB1 and CB2, as well as other receptors including TRPV1 and 5-HT1A, contributing to its diverse pharmacological effects. Notably, CBD has been approved by the FDA for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in the form of Epidiolex. Additionally, CBD demonstrates anti-inflammatory, anxiolytic, and neuroprotective properties.
CBD is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material. It is manufactured in compliance with Good Manufacturing Practices (GMP), making it suitable for FDA-regulated human clinical trials.
IUPAC Chemical Name:
(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
Common Synonyms: Marinol, Synthetic delta-9-THC
CAS Number: 1972-08-3
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN): 7370
Dronabinol is the synthetic form of delta-9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of cannabis. It is used therapeutically to alleviate nausea and vomiting associated with chemotherapy and to stimulate appetite in patients with AIDS. Dronabinol binds to CB1 receptors in the brain, affecting neurotransmitter release and modulating symptoms such as nausea and pain.
Dronabinol is produced in a GMP-compliant environment, ensuring its suitability for FDA-regulated clinical trials. Dronabinol is also available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
Common Synonyms:
Delta-8-THC, Delta-8-Tetrahydrocannabinol
CAS Number: 5957-75-5
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN): 7370
Delta-8-THC is an isomer of delta-9-THC, differing by the position of a double bond in the cannabinoid structure. It is known for producing milder psychoactive effects compared to delta-9-THC and is being investigated for potential benefits in antiemesis, anxiolysis, appetite stimulation, analgesia, and neuroprotection. Delta-8-THC binds to CB1 receptors similarly to delta-9-THC but with less potency, resulting in reduced psychoactive effects.
Delta-8-THCt is produced under GMP conditions, suitable for FDA-regulated clinical trials. Delta-8-THC is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Common Synonyms: Cannabidivarin, CBDV
CAS Number: 24274-48-4
DEA Schedule: Not Scheduled
Controlled Substances Code Number (CSCN): NA
Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in the Cannabis plant, structurally similar to CBD. It has been studied for its potential in treating epilepsy and autism spectrum disorders. CBDV exhibits anticonvulsant properties and is being explored for its effects on neurodevelopmental disorders. CBDV is produced in GMP-compliant facilities, ensuring its quality for FDA-regulated human trials.
CBDV is synthetically produced and also available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
Common Synonyms: THCV, Tetrahydrocannabivarin
CAS Number: 31262-37-0
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN): 7370
Tetrahydrocannabivarin (THCV) is a cannabinoid found in cannabis, similar to THC but with different effects, such as appetite suppression and potential antipsychotic properties. THCV acts as a CB1 receptor antagonist at low doses and a CB1 receptor agonist at higher doses, contributing to its unique pharmacological profile.
THCV is produced under GMP conditions, suitable for FDA-regulated clinical trials. THCV is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
6,6,9-trimethyl-3-pentyl-benzo[c]chromen-1-ol
Common Synonyms: CBN, Cannabinol
CAS Number: 521-35-7
DEA Schedule: Not Scheduled
Controlled Substances Code Number (CSCN): NA
Cannabinol (CBN) is a mildly psychoactive cannabinoid found in cannabis, often resulting from the oxidation of THC. It has been studied for its sedative effects and potential antibacterial properties. CBN interacts with the CB1 and CB2 receptors, albeit with less affinity compared to THC.
CBN is produced in compliance with GMP, ensuring its suitability for FDA-regulated trials. CBN is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
[3-(2- Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate
Common Synonyms:
Psilocybin, 4-Phosphoryloxy-N,N-dimethyltryptamine
CAS Number: 520-52-5
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN):7437
Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. It is converted into psilocin in the body, which has psychoactive properties. Psilocybin primarily acts on serotonin receptors, particularly 5-HT2A, leading to altered perception and cognition. It is being studied for its potential to treat depression, anxiety, and PTSD, demonstrating promising results in clinical trials.
Psilocybin is produced under GMP conditions, suitable for FDA-regulated clinical trials, and is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
3-[2(Dimethylamino)ethyl]-1H-indol-4-ol
Common Synonyms:
Psilocin, 4-Hydroxy-N,N-dimethyltryptamine
CAS Number: 520-53-6
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN): 7348
Psilocin is the active metabolite of psilocybin, responsible for its psychoactive effects. It primarily acts as a partial agonist at serotonin receptors, particularly 5-HT2A, 5-HT2C, and 5-HT1A, contributing to its hallucinogenic properties. Psilocin is being investigated for therapeutic applications in treating mental health conditions such as depression and anxiety.
Psilocin is produced in compliance with GMP for FDA-regulated trials and is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
2-(1H-Indol-3-yl)-N,N-dimethylethanamine
Common Synonyms:
DMT, N,N-Dimethyltryptamine, Dimitri
CAS Number: 61-50-7
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN): 7435
N,N-Dimethyltryptamine (DMT) is a naturally occurring psychedelic compound found in various plants and animals. It is known for its powerful and short-lasting psychoactive effects. DMT primarily acts on serotonin receptors, particularly 5-HT2A, leading to intense visual and auditory hallucinations. It is being studied for its potential therapeutic applications in treating conditions like depression and PTSD.
DMT is produced under GMP conditions, suitable for FDA-regulated clinical trials, and is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
5-Methoxy-2-(N,N-dimethylamino)ethylindole
Common Synonyms:
5-MeO-DMT, 5-Methoxy-N,N-dimethyltryptamine
CAS Number: 1019-45-0
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN): 7431
5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a naturally occurring psychedelic compound found in various plants and the venom of certain toads. It is known for its intense and short-lasting psychoactive effects. 5-MeO-DMT acts on serotonin receptors, particularly 5-HT1A and 5-HT2A, contributing to its powerful hallucinogenic effects. It is being explored for potential therapeutic applications in treating conditions such as depression and anxiety.
5-MeO-DMT is produced under GMP conditions, suitable for FDA-regulated clinical trials, and is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
IUPAC Chemical Name:
(RS)-1-(benzo[d][1,3]dioxol-5-yl)-N-methylpropan-2-amine
Common Synonyms:
MDMA, Ecstasy, XTC, Adam, 3,4-Methylenedioxymethamphetamine
CAS Number: 42542-10-9
DEA Schedule: Schedule I
Controlled Substances Code Number (CSCN): 7405
Racemic MDMA HCl, commonly known as Ecstasy, is a synthetic psychoactive drug with both stimulant and hallucinogenic properties. It acts primarily by increasing the release of serotonin, dopamine, and norepinephrine in the brain, resulting in heightened mood, energy, and perception. MDMA is being studied for its potential therapeutic applications in the treatment of PTSD and other psychiatric disorders.
rac-MDMA HCl is produced in a GMP-compliant manner, suitable for FDA-regulated clinical trials, and is available as GLP material for preclinical toxicology studies or as non-GMP research grade material.
As Controlled Substance Experts, we bring unmatched knowledge and precision to every stage of API development and manufacturing. Explore our detailed white paper to discover how Benuvia’s innovative solutions, cutting-edge technologies, and regulatory expertise can help you navigate challenges, ensure compliance, and achieve success in our highly specialized field.
Mr. Awuah-Mensah has a Pharm.D. degree with over 13 years of experience in the Pharmaceutical Industry. Prior to joining Benuvia, Mr. Awuah-Mensah worked for Insys Manufacturing, Austin Pharma, and Hospira. Godfrey is responsible for API and Drug Product Manufacturing.
"*" indicates required fields
